Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
about
Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.Development of Companion DiagnosticsThe ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancerAccurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersResponse biomarkers: re-envisioning the approach to tailoring drug therapy for cancerDigital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune responseImpact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationPathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.Who would have thought a single Ki67 measurement would predict long-term outcome?PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkersDevelopment of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.Neoadjuvant Endocrine Therapy in Breast CancerUse of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancerDesigning adjuvant treatment based on biological measurements in the neoadjuvant settingRelationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.PTEN and Ki67 expression is associated with clinicopathologic features of non-small cell lung cancer.Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancerRandomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-basEffects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptorsLongitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancerEffect of tamoxifen and raloxifene on the proliferative activity of the breast epithelium in premenopausal women.Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupPresurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.Measuring proliferation in breast cancer: practicalities and applications.Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancerCombination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancerTreatment-induced cell cycle kinetics dictate tumor response to chemotherapyLandscape of neoadjuvant therapy for breast cancerDifferentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewMolecular response to aromatase inhibitor treatment in primary breast cancer.Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based studyA study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts.Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistanceClinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
P2860
Q24810287-A5F4D837-05DC-4BC1-B633-AD3F1DBC1CE9Q25257848-525E63AA-2C7B-4B5D-AC9F-0C2B934DDE39Q26774670-261B3C3E-239A-4CAD-ACFA-AF6CE87CD348Q26786704-12E9D3F7-847F-4200-9696-098450F41ED9Q28069856-37DE2F91-63FE-4023-BF21-012BAA83A8AAQ28074295-816F26D7-B2DA-4BE4-A2E8-594F8FB4A10EQ28533543-5998932D-7B42-4CAD-848F-817BCCA3CD7BQ30369607-0DF9FD7F-87D9-4DE7-A635-D5788402B62FQ33494720-E03F6DA3-05B9-4D87-AF36-1D6351CC2C51Q33555522-1EC9F20D-CA2C-4738-BF4B-10D05298F42DQ33610437-8AD9FA7B-6D7E-46FB-B7EC-60BAAEB31F04Q33688564-12951FF0-6B1F-46BA-856C-0F4A6FB7188EQ33830320-A25A0EE6-0131-4187-A6DF-8C027D0050DAQ33917455-BC0ADD35-18F4-45A3-8214-1C1135D8B116Q34096272-1176F9A9-9D0F-4C22-B383-D0E53F17B249Q34174466-AB8D95DE-841E-4D77-996B-A49E8774BC4EQ34423533-1F2B946C-E813-4A1D-B2AB-75644D918A8CQ34486201-15940832-9334-40BE-AA9D-38AED0966F5AQ34606601-F2338BBB-5440-4A69-9509-096CD3F24426Q34991926-2AD62DBB-A5CF-417D-A47B-16948290A8BEQ35023441-6FFE1BEF-6DCC-4778-8E99-9CC66EB37C52Q35052293-C681A57F-42DD-41B2-BE3F-DCE16C166D12Q35143049-D6C36F5C-7D83-499D-B32A-9C6338F4D60EQ35145443-642DAD6A-C422-49FC-884D-F42F1DCC5A61Q35179983-15F07290-F704-477D-AF9E-B06856811247Q35552069-DD62338E-27EF-4CAB-A33A-47BFB5C6DC66Q35619082-FA348DBC-FDBA-4761-9FBD-98F29B1D33B1Q35633693-33A4D018-22A4-4EB8-96DD-9B3ECA20CBBEQ35653510-781E96F5-5241-4F5C-9381-3F3B6F196E70Q35677725-C4D2EF3F-F210-4B7D-BF18-E1077B9FE1E5Q35740145-76DDF34C-A863-4C96-8040-2F3124A094D7Q35794915-5D763D1E-51C9-47B1-82AE-2FF54B85DF3CQ35875007-F22BEAC6-6A6A-440F-9864-3FFF1D48F72AQ35904441-C0E94C98-ED17-4911-90D3-C0A895F0C39CQ35906338-B614E3EB-B436-4708-8576-ECE6A90E451EQ35944405-2E62F650-630B-4E2B-A88D-15EFB63B606AQ35958151-296D47C0-CC74-4024-80D7-C3CA7FC0E521Q35960231-85D39C29-83AF-49B7-A3A1-3DC0FD9E7404Q36013029-FF138654-F8EB-4488-9784-75A8CF52CE70Q36287107-532F327F-3F99-462F-85EA-34D51BAA1299
P2860
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Short-term changes in Ki-67 du ...... with recurrence-free survival.
@en
Short-term changes in Ki-67 du ...... with recurrence-free survival.
@nl
type
label
Short-term changes in Ki-67 du ...... with recurrence-free survival.
@en
Short-term changes in Ki-67 du ...... with recurrence-free survival.
@nl
prefLabel
Short-term changes in Ki-67 du ...... with recurrence-free survival.
@en
Short-term changes in Ki-67 du ...... with recurrence-free survival.
@nl
P2093
P1476
Short-term changes in Ki-67 du ...... with recurrence-free survival.
@en
P2093
Anthony Skene
Clive Griffith
Geraldine Walsh
IMPACT Trialists
Ian E Smith
Irene Boeddinghaus
J Michael Dixon
Janine Salter
Margaret Hills
Simone Detre
P304
P407
P433
P577
2005-01-01T00:00:00Z